HRMY
Harmony Biosciences Holdings, Inc.
NASDAQ · Healthcare · Biotechnology · US
$38.76
+0.44%Oct 20, 2026, 12:05 UTC
Harmony Biosciences announced that it will report its third-quarter 2026 financial results on November 4, 2026, before U.S. markets open, and host a conference call and webcast at 8:30 a.m. ET.
Source:Oct 12, 2026, 14:14 UTC
Harmony Biosciences Holdings, Inc. shares fell Monday following the CEO transition announcement.
Source:Oct 12, 2026, 14:14 UTC
Harmony Biosciences Holdings, Inc. announced that CEO Jeffrey Dayno will transition out of the role at the end of the year.
Source:Oct 1, 2026, 12:05 UTC
Harmony Biosciences announced it will present a poster on its ongoing Phase 3 trials of HBS-301, including ONSTRIDE-1 in narcolepsy and ONSTRIDE-2 in idiopathic hypersomnia, at the 17th European Narcolepsy Days in Bern, Switzerland on October 2-3, 2026.
Source:Aug 20, 2026, 07:18 UTC
Aurora Investment Counsel acquired a new position in Harmony Biosciences Holdings, Inc., purchasing 65,148 shares valued at approximately $2.37 million, as disclosed in a recent SEC filing.
Source:Aug 14, 2026, 14:05 UTC
Harmony Biosciences highlighted record quarterly performance for its narcolepsy treatment WAKIX and outlined development plans across its orexin, epilepsy and pitolisant lifecycle-management programs during Piper Sandler's virtual CNS Symposium.
Source:Aug 4, 2026, 11:30 UTC
Harmony Biosciences announced initial Phase 1 clinical data for its orexin-2 agonist BP-205, showing favorable pharmacokinetic and safety profiles, and plans to initiate Phase 1b and Phase 2 trials in 2026 and 2027.
Source:Aug 4, 2026, 11:30 UTC
Harmony Biosciences announced that its Pitolisant GR NDA was accepted by the FDA in July, with a target PDUFA date of April 1, 2027.
Source:Jul 16, 2026, 12:30 UTC
Harmony Biosciences preannounced record quarterly revenue of approximately $261 million for Q2 2026, representing 30% year-over-year growth, and reaffirmed full-year 2026 revenue guidance.
Jul 16, 2026, 12:30 UTC
Harmony Biosciences announced a CFO transition.
Source: